Atrial Fibrillation and Aortic Ectasia as Complications of Primary Aldosteronism: Focus on Pathophysiological Aspects

Primary aldosteronism (PA) is the most common cause of secondary hypertension. A growing body of evidence has suggested that, beyond its well-known effects on blood pressure and electrolyte balance, aldosterone excess can exert pro-inflammatory, pro-oxidant and pro-fibrotic effects on the kidney, blood vessels and heart, leading to potentially harmful pathophysiological consequences. In clinical studies, PA has been associated with an increased risk of cardiovascular, cerebrovascular, renal and metabolic complication compared to essential hypertension, including atrial fibrillation (AF) and aortic ectasia. An increased prevalence of AF in patients with PA has been demonstrated in several clinical studies. Aldosterone excess seems to be involved in the pathogenesis of AF by inducing cardiac structural and electrical remodeling that in turn predisposes to arrhythmogenicity. The association between PA and aortic ectasia is less established, but several studies have demonstrated an effect of aldosterone on aortic stiffness, vascular smooth muscle cells and media composition that, in turn, might lead to an increased risk of aortic dilation and dissection. In this review, we focus on the current evidence regarding the potential role of aldosterone excess in the pathogenesis of AF and aortic ectasia.

[1]  J. Finnie,et al.  Histological regional analysis of the aortic root and thoracic ascending aorta: a complete analysis of aneurysms from root to arch , 2021, Journal of Cardiothoracic Surgery.

[2]  G. Wells,et al.  Aortic Stiffness, Central Blood Pressure, and Pulsatile Arterial Load Predict Future Thoracic Aortic Aneurysm Expansion , 2020, Hypertension.

[3]  C. Hung,et al.  Left ventricular remodeling and dysfunction in primary aldosteronism , 2020, Journal of Human Hypertension.

[4]  Jeroen J. Bax,et al.  2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). , 2020, European heart journal.

[5]  F. Luo,et al.  Is primary aldosteronism a potential risk factor for aortic dissection? A case report and literature review , 2020, BMC Endocrine Disorders.

[6]  P. Hopkins,et al.  The Unrecognized Prevalence of Primary Aldosteronism , 2020, Annals of Internal Medicine.

[7]  M. Parasiliti-Caprino,et al.  Prevalence of primary aldosteronism and association with cardiovascular complications in patients with resistant and refractory hypertension. , 2020, Journal of hypertension.

[8]  G. Parati,et al.  The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism , 2020, International Journal of Cardiology. Hypertension.

[9]  M. Muiesan,et al.  Atrial fibrillation as presenting sign of primary aldosteronism: results of the Prospective Appraisal on the Prevalence of Primary Aldosteronism in Hypertensive (PAPPHY) study. , 2019, Journal of hypertension.

[10]  F. Beygui,et al.  Effects of Mineralocorticoid Receptor Antagonists on Atrial Fibrillation Occurrence: A Systematic Review, Meta‐Analysis, and Meta‐Regression to Identify Modifying Factors , 2019, Journal of the American Heart Association.

[11]  L. Sechi,et al.  Renal damage in primary aldosteronism: a systematic review and meta-analysis. , 2019, Journal of hypertension.

[12]  P. M. van de Ven,et al.  Hypertension with primary aldosteronism is associated with increased carotid intima‐media thickness and endothelial dysfunction , 2019, Journal of clinical hypertension.

[13]  G. Di Dalmazi,et al.  Larger ascending aorta in primary aldosteronism: a 3-year prospective evaluation of adrenalectomy vs. medical treatment , 2018, Endocrine.

[14]  G. Curhan,et al.  Renal Outcomes in Medically and Surgically Treated Primary Aldosteronism , 2018, Hypertension.

[15]  Youbin Deng,et al.  Enlarged Size and Impaired Elastic Properties of the Ascending Aorta are Associated with Endothelial Dysfunction and Elevated Plasma Matrix Metalloproteinase-2 Level in Patients with Bicuspid Aortic Valve. , 2018, Ultrasound in medicine & biology.

[16]  C. Zoccali,et al.  Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term , 2018, Hypertension.

[17]  M. Lombès,et al.  Specific Activation of the Alternative Cardiac Promoter of Cacna1c by the Mineralocorticoid Receptor , 2018, Circulation research.

[18]  A. Rosengren,et al.  Primary aldosteronism and thyroid disorders in atrial fibrillation: A Swedish nationwide case–control study , 2018, European Journal of Preventive Cardiology.

[19]  Hong-zhao Li,et al.  Mineralocorticoid receptor antagonism protects the aorta from vascular smooth muscle cell proliferation and collagen deposition in a rat model of adrenal aldosterone-producing adenoma , 2017, Journal of Physiology and Biochemistry.

[20]  G. Johannsson,et al.  Aldosterone to Renin Ratio as a Screening Instrument for Primary Aldosteronism in a Middle-Aged Population with Atrial Fibrillation , 2017, Hormone and Metabolic Research.

[21]  W. Young,et al.  Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. , 2017, The lancet. Diabetes & endocrinology.

[22]  R. Touyz,et al.  Vascular dysfunction and fibrosis in stroke-prone spontaneously hypertensive rats: The aldosterone-mineralocorticoid receptor-Nox1 axis , 2017, Life sciences.

[23]  Emelia J. Benjamin,et al.  Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes , 2017, Circulation research.

[24]  F. Veglio,et al.  Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. , 2017, Journal of the American College of Cardiology.

[25]  P. Sanders,et al.  Aldosterone Pathway Blockade to Prevent Atrial Fibrillation: A Systematic Review and Meta-Analysis. , 2017, International journal of cardiology.

[26]  Zhilin Qu,et al.  Electrophysiology of Hypokalemia and Hyperkalemia. , 2017, Circulation. Arrhythmia and electrophysiology.

[27]  Yen-Hung Lin,et al.  Long term outcome of Aldosteronism after target treatments , 2016, Scientific Reports.

[28]  Tong Liu,et al.  Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[29]  W. Young,et al.  The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. , 2016, The Journal of clinical endocrinology and metabolism.

[30]  M. Novello,et al.  Aldosterone and Left Ventricular Remodeling , 2015, Hormone and Metabolic Research.

[31]  M. Metra,et al.  The effect of aldosterone-antagonist therapy on aortic elastic properties in patients with nonischemic dilated cardiomyopathy , 2015, Journal of cardiovascular medicine.

[32]  A. Nakashima,et al.  Effect of Aldosterone-Producing Adenoma on Endothelial Function and Rho-Associated Kinase Activity in Patients With Primary Aldosteronism , 2015, Hypertension.

[33]  I. Komuro,et al.  Impairment of flow-mediated dilation correlates with aortic dilation in patients with Marfan syndrome , 2014, Heart and Vessels.

[34]  Shun-Fa Yang,et al.  Cross-talk between mineralocorticoid receptor/angiotensin II type 1 receptor and mitogen-activated protein kinase pathways underlies aldosterone-induced atrial fibrotic responses in HL-1 cardiomyocytes. , 2013, International journal of cardiology.

[35]  D. V. Van Wagoner,et al.  Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling. , 2013, International journal of cardiology.

[36]  R. Weiss,et al.  Oxidized Ca2+/Calmodulin-Dependent Protein Kinase II Triggers Atrial Fibrillation , 2013, Circulation.

[37]  U. Laufs,et al.  The Mineralocorticoid Receptor Promotes Fibrotic Remodeling in Atrial Fibrillation* , 2014, The Journal of Biological Chemistry.

[38]  A. Pessina,et al.  Long-Term Control of Arterial Hypertension and Regression of Left Ventricular Hypertrophy With Treatment of Primary Aldosteronism , 2013, Hypertension.

[39]  Shu Liu,et al.  Mineralocorticoid Receptor Agonists Induce Mouse Aortic Aneurysm Formation and Rupture in the Presence of High Salt , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[40]  N. Brown Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis , 2013, Nature Reviews Nephrology.

[41]  C. Delcayre,et al.  Aldosterone Mediates Cardiac Fibrosis in the Setting of Hypertension , 2013, Current Hypertension Reports.

[42]  E. Schiffrin,et al.  Vascular Actions of Aldosterone , 2012, Journal of Vascular Research.

[43]  M. Allessie,et al.  Aldosterone promotes atrial fibrillation. , 2012, European heart journal.

[44]  U. Hoppe,et al.  Spironolactone Prevents Aldosterone Induced Increased Duration of Atrial Fibrillation in Rat , 2012, Cellular Physiology and Biochemistry.

[45]  S. Mildenberger,et al.  Influence of Aldosterone and Salt or Ouabain in A10 Rat Aorta Smooth Muscle Cells , 2012, Journal of Vascular Research.

[46]  Mark E. Anderson,et al.  Oxidation of CaMKII determines the cardiotoxic effects of aldosterone , 2011, Nature Medicine.

[47]  J. Schreieck,et al.  Effects of selective mineralocorticoid receptor antagonism on atrial ion currents and early ionic tachycardia-induced electrical remodelling in rabbits , 2010, Naunyn-Schmiedeberg's Archives of Pharmacology.

[48]  Y. Li,et al.  Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing , 2010, British journal of pharmacology.

[49]  M. Iida,et al.  Role of Rho kinase and oxidative stress in cardiac fibrosis induced by aldosterone and salt in angiotensin type 1a receptor knockout mice , 2010, Regulatory Peptides.

[50]  K. Kuo,et al.  Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. , 2010, Journal of the American College of Cardiology.

[51]  J. Floras,et al.  Endothelial function, carotid-femoral stiffness, and plasma matrix metalloproteinase-2 in men with bicuspid aortic valve and dilated aorta. , 2010, Journal of the American College of Cardiology.

[52]  B. Wożakowska-Kapłon,et al.  A Decrease in Serum Aldosterone Level is Associated with Maintenance of Sinus Rhythm after Successful Cardioversion of Atrial Fibrillation , 2010, Pacing and clinical electrophysiology : PACE.

[53]  G. Lip,et al.  Atrial fibrillation in primary aldosteronism , 2009, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[54]  K. Weber,et al.  Coupled Calcium and Zinc Dyshomeostasis and Oxidative Stress in Cardiac Myocytes and Mitochondria of Rats With Chronic Aldosteronism , 2009, Journal of cardiovascular pharmacology.

[55]  F. Jaisser,et al.  Mineralocorticoid Modulation of Cardiac Ryanodine Receptor Activity Is Associated With Downregulation of FK506-Binding Proteins , 2009, Circulation.

[56]  G. Fishman,et al.  Gap Junction Remodeling and Spironolactone-Dependent Reverse Remodeling in the Hypertrophied Heart , 2009, Circulation research.

[57]  J. Sowers,et al.  Mineralocorticoid Receptor Antagonism Attenuates Vascular Apoptosis and Injury via Rescuing Protein Kinase B Activation , 2009, Hypertension.

[58]  L. Ghiadoni,et al.  Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism , 2008, Journal of hypertension.

[59]  S. Nattel,et al.  Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. , 2008, Journal of the American College of Cardiology.

[60]  L. Sechi,et al.  Cardiovascular outcomes in patients with primary aldosteronism after treatment. , 2008, Archives of internal medicine.

[61]  W. Han,et al.  Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs. , 2008, Chinese medical journal.

[62]  J. Egido,et al.  Interactions between aldosterone and connective tissue growth factor in vascular and renal damage in spontaneously hypertensive rats , 2007, Journal of hypertension.

[63]  S. Mildenberger,et al.  Altered collagen homeostasis in human aortic smooth muscle cells (HAoSMCs) induced by aldosterone , 2007, Pflügers Archiv - European Journal of Physiology.

[64]  T. Zelinka,et al.  Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension. , 2006, American journal of hypertension.

[65]  A. Shah,et al.  Aldosterone mediates angiotensin II‐induced interstitial cardiac fibrosis via a Nox2‐containing NADPH oxidase , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[66]  C. Massey,et al.  Is Primary Hyperaldosteronism a Risk Factor for Aortic Dissection? , 2006, Cardiology.

[67]  F. Jaisser,et al.  A direct relationship between plasma aldosterone and cardiac L‐type Ca2+ current in mice , 2005, The Journal of physiology.

[68]  E. Vicaut,et al.  Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. , 2005, European heart journal.

[69]  S. Barrère‐lemaire,et al.  Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes. , 2005, Cardiovascular research.

[70]  G. Fishman,et al.  Data Supplement (unedited) at: , 2005 .

[71]  P. Milliez,et al.  Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. , 2005, Journal of the American College of Cardiology.

[72]  R. Liao,et al.  Mineralocorticoid Receptor Inhibition Ameliorates the Transition to Myocardial Failure and Decreases Oxidative Stress and Inflammation in Mice With Chronic Pressure Overload , 2005, Circulation.

[73]  D. Calhoun,et al.  Impaired Endothelium-Dependent Flow-Mediated Vasodilation in Hypertensive Subjects With Hyperaldosteronism , 2004, Circulation.

[74]  J. Blacher,et al.  [Primary aldosteronism. A risk factor for aortic dissection?]. , 2003, Journal des maladies vasculaires.

[75]  J. Delyani,et al.  Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. , 2002, Endocrinology.

[76]  M. Safar,et al.  Increased Carotid Wall Elastic Modulus and Fibronectin in Aldosterone-Salt–Treated Rats: Effects of Eplerenone , 2002, Circulation.

[77]  K. Weber,et al.  Aldosterone-induced inflammation in the rat heart : role of oxidative stress. , 2002, The American journal of pathology.

[78]  E. Schiffrin,et al.  Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. , 2002, American journal of hypertension.

[79]  A. Goette,et al.  Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. , 2001, The American journal of cardiology.

[80]  M. Safar,et al.  Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. , 2001, Journal of the American College of Cardiology.

[81]  G. Vassort,et al.  Aldosterone Upregulates Ca2+ Current in Adult Rat Cardiomyocytes , 1999 .

[82]  L. Clark,et al.  Coronary Artery Aneurysms, Aortic Dissection, and Hypertension Secondary to Primary Aldosteronism: A Rare Triad , 1999, Angiology.

[83]  A. Somlyo Signal transduction: Rhomantic interludes raise blood pressure , 1997, Nature.

[84]  K. Weber,et al.  Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. , 1997, Cardiovascular research.

[85]  M. Safar,et al.  Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[86]  E. Baulieu,et al.  Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. , 1992, Circulation research.

[87]  M. Akahoshi,et al.  Elevation of plasma renin activity during pregnancy and rupture of a dissecting aortic aneurysm in a patient with primary aldosteronism. , 1983, Japanese heart journal.

[88]  G. Curhan,et al.  Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. , 2018, The lancet. Diabetes & endocrinology.

[89]  Fiorenzo Gaita,et al.  Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. , 2018, The lancet. Diabetes & endocrinology.

[90]  Hong-zhao Li,et al.  Aortic cell apoptosis in rat primary aldosteronism model , 2010, Journal of Huazhong University of Science and Technology [Medical Sciences].

[91]  K. Lam,et al.  The clinicopathologic significance of unilateral adrenal cortical hyperplasia: Report of an unusual case and a review of the literature , 1999, Endocrine pathology.